Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Farmers Insurance
Boehringer Ingelheim
US Department of Justice

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,286,754

« Back to Dashboard

Summary for Patent: 5,286,754

Title: Pharmaceutical formulations of ciprofloxacin
Abstract:A pharmaceutical formulation comprising by weight 30 to 95% of 1cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-quinoline-3-carb oxylic acid; 4.5 to 25% of a dry binder based on cellulose; 0 to 30% of a disintegration auxiliary based on starch; 0.5 to 10% of a disintegration auxiliary based on a cellulose derivative and/or a cross-linked polyvinyl-pyrrolidone; 0 to 2% of a flow-improving agent, and 0 to 3% of a lubricant. Tablets and capsules made from granules of the formulation, about 0.8 to 2 mm in size, exhibit high bioavailability and excellent storage stability.
Inventor(s): Streuff; Bernd (Wermelskirchen, DE), Luchtenberg; Helmut (Niederkassel, DE)
Assignee: Bayer Aktiengesellschaft (Leverkusen, DE)
Application Number:07/246,576
Patent Claim Types:
see list of patent claims
Formulation; Compound;

No matches for this query

Foreign Priority and PCT Information for Patent: 5,286,754

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany3601566Jan 21, 1986

International Patent Family for Patent: 5,286,754

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Hong Kong63196► Subscribe
Germany3601566► Subscribe
Germany3770001► Subscribe
European Patent Office0230881► Subscribe
Spain2038128► Subscribe
Greece3001953► Subscribe
China87100810► Subscribe
China1084188► Subscribe
HungaryT42951► Subscribe
Canada1296634► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Fish and Richardson
Express Scripts
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: